PJ PEPTIDESResearch, made understandable.LATEST NEWS / SOURCE-FIRST
Research moves quickly. Every update here links to its source, identifies what kind of evidence it is and separates an interesting finding from a proven conclusion.
Phase 3 update
Lilly reported results from two additional obesity trials. Retatrutide remains investigational; company announcements are not the same as FDA approval or a peer-reviewed final publication.
Open original source · Eli Lilly ↗Peer-reviewed research
Two large trials reported body-weight outcomes in adults with obesity, including a trial in people with type 2 diabetes. The combination remains distinct from cagrilintide alone.
Open original source · PubMed / NEJM ↗Safety and regulation
FDA's continuously maintained review identifies limited human safety information or other concerns for compounds including BPC-157, GHK-Cu, MOTS-C and Melanotan II.
Open original source · U.S. FDA ↗OUR PUBLISHING STANDARD
Use primary sources.
Government information, trial registries and peer-reviewed research take priority.
Name the evidence level.
Cell, animal, observational and controlled human studies are never treated as interchangeable.
State the limitations.
Promising does not mean proven, approved, safe or appropriate for an individual.